NRX Pharmaceuticals Inc
NRXP
Company Profile
Business description
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Contact
1201 Orange Street
Suite 600
WilmingtonDE19801
USAT: +1 484 254-6134
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks
New data centre deal for ASX listed REIT
New parternship adds to a growing data centre pipeline in fiscal 2026.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,035.50 | 1.40 | -0.02% |
| CAC 40 | 8,195.21 | 45.71 | 0.56% |
| DAX 40 | 24,539.34 | 48.93 | 0.20% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,951.14 | 19.76 | 0.20% |
| HKSE | 26,338.47 | 707.93 | 2.76% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 51,544.01 | 1,204.53 | 2.39% |
| NZX 50 Index | 13,573.17 | 24.75 | 0.18% |
| S&P 500 | 6,858.47 | 12.97 | 0.19% |
| S&P/ASX 200 | 8,727.80 | 1.80 | 0.02% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |